clinical trial · NCT07691606
A Study of ARC-02 in B-cell NHL
Taiho Oncology, Inc.·phase1·recruiting·n = 140
B-cell Non Hodgkin LymphomaARC-02Rituximab
brief summary
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
started
Jun 22, 2026
primary completion
Jan 1, 2029
completion
Dec 1, 2030
last updated
Oct 8, 2026
official title
A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol